

<b>Notice of Allowability</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	10/823,987	LLOYD ET AL.
	Examiner Deepak Rao	Art Unit 1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTO-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1.  This communication is responsive to 4/14/04.
2.  The allowed claim(s) 18-24 are 18-24.
3.  The drawings filed on \_\_\_\_\_ are accepted by the Examiner.
4.  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a)  All
  - b)  Some\*
  - c)  None
 of the:
  1.  Certified copies of the priority documents have been received.
  2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3.  Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.


Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  
**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

5.  A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6.  CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
  - (a)  including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached
    - 1)  hereto or 2)  to Paper No./Mail Date \_\_\_\_\_.
  - (b)  including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7.  DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

#### Attachment(s)

1.  Notice of References Cited (PTO-892)
2.  Notice of Draftperson's Patent Drawing Review (PTO-948)
3.  Information Disclosure Statements (PTO-1449 or PTO/SB/08),  
Paper No./Mail Date 06162004
4.  Examiner's Comment Regarding Requirement for Deposit  
of Biological Material
5.  Notice of Informal Patent Application (PTO-152)
6.  Interview Summary (PTO-413),  
Paper No./Mail Date \_\_\_\_\_.
7.  Examiner's Amendment/Comment
8.  Examiner's Statement of Reasons for Allowance
9.  Other \_\_\_\_\_.



Deepak Rao  
Primary Examiner  
Art Unit: 1624

### **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Ms. Deanna Baxam on September 27, 2004.

The application has been amended as follows:

#### **In the Specification:**

Replace the continuing data in the first paragraph with the following:

-- This is a division of U.S. application Serial No. 10/295,404 filed November 15, 2002 now U.S. Patent 6,784,189 which is a division of U.S. Application Serial No. 09/670,285 filed September 25, 2000 now U.S. Patent 6,511,977, which is a division of U.S. application Serial No. 09/375,955 filed August 17, 1999, now U.S. Patent 6,150,356 which claims priority from U.S. provisional application Serial No. 60/098,709 filed September 1, 1998. --

#### **In the Claims:**

In the listing of claims, delete " 1-18. Cancelled" and in place insert -- 1-17. (canceled) --.

Renumber claims 19-25 according to Rule 1.121 as claims 18-24 and amend renumbered claims 19-24 to depend from claim 18.


*(See Appendix for listing of claims after the above amendments).*

## REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance:

The references of record do not teach or fairly suggest the instantly claimed indanyl derivatives useful as pharmaceutical therapeutic agents having potassium channel inhibitory activity. See e.g., WO 98/04521, teaches selective inhibitors of potassium channel (see formula I), however, does not teach or fairly suggest compounds structurally analogous to the claimed compounds, i.e., having a Q group as defined for the instant claims.

**Note:** The instant application is a divisional of U.S. S. No. 10/295,404 (now U.S. Patent No. 6,784,189) wherein a restriction was required and claims drawn to compounds wherein X<sup>1</sup> is



were allowed, which is clearly evident from the records of the allowed application (see amendment filed on February 2, 2004). The claim 1 of US 6,784,189 however, inadvertently contains some extraneous text in the definition of X<sup>1</sup> that should not be present.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Receipt is acknowledged of the Information Disclosure Statement filed on June 16, 2004 and a copy is enclosed herewith.


***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Deepak Rao whose telephone number is (571) 272-0672. The examiner can normally be reached on Tuesday-Friday from 6:30am to 5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Mukund Shah, can be reached on (571) 262-0674. If you are unable to reach Dr. Shah within a 24 hour period, please contact James O. Wilson, Acting-SPE of 1624 at (571) 272-0661. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

  
Deepak Rao  
Primary Examiner  
Art Unit 1624

September 28, 2004

Application/Control Number: 10/823,987  
Art Unit: 1624

Page 5

## **APPENDIX**